Arzeda
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2009 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 79
- Registered name
- Arzeda Corp Seattle business license
- Total raised
- $82.9M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $4.5M · Aug 2025 SEC Form D
- Founders
- David Baker, Alexandre Zanghellini
TerraPower Isotopes’ Chris Dunckley Leads Team Extracting Ultra-Rare Actinium-225 from Cold War Waste for Cancer Therapy
Chris Dunckley, director of chemistry and engineering at TerraPower Isotopes, leads a multidisciplinary team extracting the ultra-rare radioisotope actinium-225 from Cold War nuclear waste to develop promising cancer therapies. His leadership and scientific expertise help transform radioactive weapons waste into potentially life-saving medical treatments.
Seattle Startup Arzeda Raises $38M to Advance Protein Design for Industrial and Agricultural Applications
Seattle-based protein design startup Arzeda raised $38 million in its latest funding round, bringing total investments to $86 million to develop enzymes for industrial and agricultural uses. The company works with major partners like Unilever, BP, and Gore-Tex makers, and was the first spinout from the University of Washington's Institute for Protein Design.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
Takeda buys Seattle startup PvP Biologics for up to $330M, will advance TAK-062 into Phase 2
Japanese pharmaceutical Takeda acquired Seattle biotech PvP Biologics for up to $330 million in late February, taking over its TAK-062 (Kuma062) program and all clinical and manufacturing activities while laying off PvP staff. Takeda plans to run phase 2 trials of the enzyme-based celiac disease treatment that PvP developed after earlier funding of $35 million supported phase 1 work.
